Bortezomib-Containing Regimens for the Treatment of Newly Diagnosed and Relapsed Amyloid Light Chain Amyloidosis: A Single-Center Experience

摘要

Bortezomib exhibits unprecedented single-agent activity in AL amyloidosis. Here, we performed a review of the use of bortezomib containing regimens to assess the rapidity and quality of response. After a median of 4 cycles, a HR was seen in 49/52 cases (94.2%) demonstrating that bortezomib is a safe and well-tolerated therapy for AL patients showing rapid HR and cardiac responses.